铂类为基础的三种化疗方案治疗晚期非小细胞肺癌的临床研究

《铂类为基础的三种化疗方案治疗晚期非小细胞肺癌的临床研究》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、现代肿瘤医学2008年3月第16卷第3期·375·铂类为基础的三种化疗方案治疗晚期非小细胞肺癌的临床研究赵亚超,朱长亮,张志培,袁远,钟代星,程庆书Clinicalstudyofthreeplatinum-basedregimensinthecombinedchemotherapyofpa2tientswithadvancedNSCLCZHAOYa-chao,ZHUChang-liang,ZHANGZhi-pei,YUANYuan,ZHONGDai-xing,CHENGQing-shuDepartmentofThoracicSurgery,TangduH

2、ospital,FourthMilitaryMedicalUniversity,Xi'an710038,China.【Abstract】Objective:ToobservetheeffectandtoxicityofTP,NPandGPregimeninthechemotherapyofpatientswithadvancednon-smallcelllungcancer(NSCLC).Methods:Totalof93casesofadvancedNSCLCpatientsweredividedintoTPgroup(31cases),NPgroup

3、(31cases)andGPgroup(31cases)randomly.Thepatientsweretreated222respectivelywithpaclitaxel135mg/m,d1;vinorelbine25mg/m,d1、8;gemcitabine1000mg/m,d1,8;cisplatin280mg/m,d1,2.Thereponserate,mediandurationofsurvivaland1yearsurvivalratewerecalculatedfinally.Re2sults:Thereponseratewas43.8

4、%inTPgroup,38.7%inNPgroup,36.7%inGPgroup;Themediandurationofsurvivalwere8.5,8.3and9.4monthsrespectively;the1yearsurvivalratewere29.4%,23.6%,and38.1%re2spectively.Theefficacyinthreegroupshadnosignificantdifference(P>0.05).Themajortoxicitieswerebonemar2rowsuppressionandgastrointest

5、inaltoxicity.TherateofbonemarrowsuppressionofTPgroupwashigherthantheoth2ergroups,andtheNPgrouphadahigherrateofphlebitisthanTPandNP.Conclusion:TP,NPandGPregimensaredefinitelyeffectiveinNSCLCpatients.Thereisnosignificantdifferenceamongthethreegroups.Theyallcanbeusedasthefirstlineth

6、erapyprotocolsforthetreatmentofadvancedNSCLCpatients.【Keywords】non-smallcelllungcancer(NSCLC);combinedchemotherapy;cisplatin;paclitaxel;vinorelbine;gem2citabine.ModernOncology2008,16(3):0375-0377【摘要】目的:观察紫杉醇(paclitaxel,Taxel)、长春瑞滨(vinorelbine,NVB)、吉西他滨(gemcitabine,GEM)分别联合顺铂(cisp

7、latin,DDP)方案对晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的疗效及毒副反应。方法:93例晚期非小细胞肺癌患者随机分为TP组(紫杉醇+顺铂)32例、NP组(长春瑞滨+顺铂)3122例、GP组(吉西他滨+顺铂)30例。给药方法:紫杉醇135mg/m,第1天;长春瑞滨25mg/m,吉西他滨221000mg/m,均在第1、8天使用;顺铂80mg/m,分2天使用。统计各组有效率(CR+PR)、中位生存期(medi2andurationofsurvival)、1年生存率(1yearsurvivalrate)。结果:TP组

8、有效率(CR+PR)为43.8%,中位生存期为8.6月,1年生存率为32.1%;